Implementing New Guidelines to Optimise Bioequivalence and Bioavailability Studies



Pharma IQ News
06/22/2010


Two thirds of clinical studies worldwide are bioequivalence studies, so who can afford not to be up to date with the latest guidelines? Companies need to leverage these regulations to ensure efficiency and accuracy when establishing bioequivalence and bioavailability.

Pharma IQ is launching a new scientific forum, Bioequivalence & Bioavailability Studies, taking place in Munich on the 26th and 27th of October. The conference will enable delegates to discuss the key challenges faced by pharmaceutical organisation in bioequivalence and bioavailability studies, such as the impact of new guidelines from EMA and FDA, changes in study design possibilities, biowaivers and considerations for modified release products, optimising bioavailability and effective approaches to outsourcing. 

As a gesture, the conference organisers are offering delegates a complimentary ‘Munich Experience’. The experiences range from city tours, to bike rides and day excursions to nearby attractions and are available to everyone who books before the 23rd of July 2010.

Speakers at the conference include; Jose Morais, Pharmaceutical Assessor, INFARMED; Kersti Oselin, Medical Assessor, MHRA; Christophe Baumgaertel, Department, Safety and Efficiency Assessment of Human Medicinal Products, AGES; Sandra van Os, Head Clinicial Operations, Synthon BV; Tamas Paal, President Scientific Board, National Institute of Pharmacy, Hungary; Carlos Camozzi, Medical Director, Orphan Europe.



---Ends---

Editors Notes. IQPC has an established reputation for delivering the highest standard of industry specific conferences, seminars and internal training programmes. We aim to keep business executives up-to date with the forefront of their industries’ trends, technological developments and regulatory landscape.

For any more information please contact: Nicola Ambler, +44 (0)20 7368 9300
nicola.ambler@iqpc.co.uk or visit www.bioequivalenceevent.com.